398 related articles for article (PubMed ID: 16321617)
1. A pharmacokinetic-pharmacodynamic disease model to predict in vivo antiviral activity of maraviroc.
Rosario MC; Jacqmin P; Dorr P; van der Ryst E; Hitchcock C
Clin Pharmacol Ther; 2005 Nov; 78(5):508-19. PubMed ID: 16321617
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic/pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients.
Rosario MC; Jacqmin P; Dorr P; James I; Jenkins TM; Abel S; van der Ryst E
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):86-94. PubMed ID: 18333870
[TBL] [Abstract][Full Text] [Related]
3. A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.
Rosario MC; Poland B; Sullivan J; Westby M; van der Ryst E
J Acquir Immune Defic Syndr; 2006 Jun; 42(2):183-91. PubMed ID: 16639345
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of short-term monotherapy with maraviroc, a new CCR5 antagonist, in patients infected with HIV-1.
Fätkenheuer G; Pozniak AL; Johnson MA; Plettenberg A; Staszewski S; Hoepelman AI; Saag MS; Goebel FD; Rockstroh JK; Dezube BJ; Jenkins TM; Medhurst C; Sullivan JF; Ridgway C; Abel S; James IT; Youle M; van der Ryst E
Nat Med; 2005 Nov; 11(11):1170-2. PubMed ID: 16205738
[TBL] [Abstract][Full Text] [Related]
5. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity.
Dorr P; Westby M; Dobbs S; Griffin P; Irvine B; Macartney M; Mori J; Rickett G; Smith-Burchnell C; Napier C; Webster R; Armour D; Price D; Stammen B; Wood A; Perros M
Antimicrob Agents Chemother; 2005 Nov; 49(11):4721-32. PubMed ID: 16251317
[TBL] [Abstract][Full Text] [Related]
6. Maraviroc, a chemokine CCR5 receptor antagonist for the treatment of HIV infection and AIDS.
Meanwell NA; Kadow JF
Curr Opin Investig Drugs; 2007 Aug; 8(8):669-81. PubMed ID: 17668369
[TBL] [Abstract][Full Text] [Related]
7. CCR5 antagonists: comparison of efficacy, side effects, pharmacokinetics and interactions--review of the literature.
Emmelkamp JM; Rockstroh JK
Eur J Med Res; 2007 Oct; 12(9):409-17. PubMed ID: 17933722
[TBL] [Abstract][Full Text] [Related]
8. The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.
Chan PL; Jacqmin P; Lavielle M; McFadyen L; Weatherley B
J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):41-61. PubMed ID: 21088872
[TBL] [Abstract][Full Text] [Related]
9. Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM; Boucher CA; Kuritzkes DR; van de Vijver DA; Llibre JM; Lewis M; Simpson P; Delogne C; McFadyen L; Chapman D; Perros M; Valdez H; van der Ryst E; Westby M
Antivir Ther; 2011; 16(3):395-404. PubMed ID: 21555822
[TBL] [Abstract][Full Text] [Related]
10. CCR5 antagonists in the treatment of treatment-naive patients infected with CCR5 tropic HIV-1.
Bredeek UF; Harbour MJ
Eur J Med Res; 2007 Oct; 12(9):427-34. PubMed ID: 17933724
[TBL] [Abstract][Full Text] [Related]
11. Reviews of anti-infective agents: maraviroc: the first of a new class of antiretroviral agents.
MacArthur RD; Novak RM
Clin Infect Dis; 2008 Jul; 47(2):236-41. PubMed ID: 18532888
[TBL] [Abstract][Full Text] [Related]
12. Maraviroc: pharmacokinetics and drug interactions.
Abel S; Back DJ; Vourvahis M
Antivir Ther; 2009; 14(5):607-18. PubMed ID: 19704163
[TBL] [Abstract][Full Text] [Related]
13. From in vitro EC₅₀ to in vivo dose-response for antiretrovirals using an HIV disease model. Part I: a framework.
Fang J; Jadhav PR
J Pharmacokinet Pharmacodyn; 2012 Aug; 39(4):357-68. PubMed ID: 22736302
[TBL] [Abstract][Full Text] [Related]
14. Treatment of HIV infection with the CCR5 antagonist maraviroc.
Kromdijk W; Huitema AD; Mulder JW
Expert Opin Pharmacother; 2010 May; 11(7):1215-23. PubMed ID: 20402558
[TBL] [Abstract][Full Text] [Related]
15. Maraviroc: new drug. Multiple antiretroviral treatment failure: too soon to reach conclusions.
Prescrire Int; 2008 Jun; 17(95):98-101. PubMed ID: 18623908
[TBL] [Abstract][Full Text] [Related]
16. How will CCR5 antagonists influence the recommendations for the antiretroviral treatment of HIV-1 infection.
van Lunzen J
Eur J Med Res; 2007 Oct; 12(9):435-40. PubMed ID: 17933725
[TBL] [Abstract][Full Text] [Related]
17. Maraviroc: a CCR5-receptor antagonist for the treatment of HIV-1 infection.
Lieberman-Blum SS; Fung HB; Bandres JC
Clin Ther; 2008 Jul; 30(7):1228-50. PubMed ID: 18691983
[TBL] [Abstract][Full Text] [Related]
18. Maraviroc: a new CCR5 antagonist.
Sayana S; Khanlou H
Expert Rev Anti Infect Ther; 2009 Feb; 7(1):9-19. PubMed ID: 19622053
[TBL] [Abstract][Full Text] [Related]
19. Maraviroc (Celsentri) for multidrug-resistant human immunodeficiency virus (HIV)-1.
Ndegwa S
Issues Emerg Health Technol; 2007 Dec; (110):1-8. PubMed ID: 18080399
[TBL] [Abstract][Full Text] [Related]
20. A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc.
Jacqmin P; McFadyen L; Wade JR
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):95-106. PubMed ID: 18333871
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
